Abstract
Atezolizumab plus bevacizumab (A+B) is the current standard systemic therapy for patients with advanced hepatocellular carcinoma (HCC). This study sought to clarify its safety and efficacy in HCC patients who had chronic hepatitis B virus (HBV) infection and high viral load (NCT04180072). The first 10 subjects in the study constituted the safety run-in cohort.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
